Vascular Screening Test: 7 Essential Facts for Independent Practices in 2026

A vascular screening test is a non-invasive evaluation that checks the major arteries for early signs of peripheral arterial disease (PAD), carotid stenosis, abdominal aortic aneurysm (AAA), and related cardiovascular risk — in at-risk patients. For independent physicians, an in-office vascular screening test built around the ankle-brachial index (ABI) and complementary autonomic and sudomotor measurements is one of the most efficient ways to identify high-risk patients in a single 7- to 10-minute visit, document medical necessity, and deliver actionable clinical information without referring the patient out.

This guide walks through seven facts that matter most for independent practices considering or already performing vascular screening in 2026: what the test includes, why undiagnosed PAD is so common, how accurate ABI really is, who should be screened, and how the CMAT Advantage program from HealthWright Technologies fits in. For related billing detail, see our ABI CPT code guide and the TM-Flow reimbursement overview.

What Is a Vascular Screening Test?

A vascular screening test is a panel of non-invasive measurements that evaluate blood flow and arterial structure in the legs, neck, and abdomen. The standard components in a comprehensive vascular screening test are: an ankle-brachial index (ABI) to assess lower-extremity arteries for PAD, a carotid duplex ultrasound to check for plaque or narrowing in the carotid arteries, and an abdominal aortic ultrasound to screen for AAA. Many in-office programs add toe-brachial index (TBI) for patients with calcified vessels, pulse volume recording (PVR), autonomic nervous system testing, and sudomotor testing to assess small-fiber nerve function. For patients with calcified vessels, that panel often adds a toe-brachial index for a more accurate reading.

The combined evaluation usually takes under 30 minutes for a basic carotid/ABI/AAA panel, or 7 to 10 minutes for an integrated office-based system like the TM-Flow that bundles ABI, autonomic, and sudomotor testing into a single workflow. None of the components require contrast, radiation, or sedation, which is why a vascular screening test is appropriate for asymptomatic risk-factor patients as well as patients with classic claudication symptoms.

Why Does a Vascular Screening Test Matter So Much in 2026?

Peripheral arterial disease is one of the most undiagnosed conditions in primary care. According to the CDC, PAD affects more than 12 million Americans. Prevalence among adults aged 40 and older is approximately 4.3%, and that number climbs to 14.5% among adults aged 70 and older. Severe PAD with chronic limb-threatening ischemia, which can lead to amputation, affects about 1.3% of all US adults. Despite those numbers, most PAD cases identified through screening studies were previously undiagnosed because patients had not yet developed claudication or because clinicians had not pursued an objective vascular workup.

That diagnostic gap is the core reason a structured in-office vascular screening test is high-leverage. PAD is both a leg-circulation problem and a powerful marker of systemic atherosclerosis. Patients with PAD have substantially higher risk of myocardial infarction, stroke, and cardiovascular death than the general population. Identifying PAD early lets the physician escalate cardiovascular risk reduction (statins, antiplatelet therapy, blood pressure management, smoking cessation support, supervised exercise), document medical necessity for downstream imaging, and follow the patient with objective serial data instead of subjective symptom reports.

What Conditions Does a Vascular Screening Test Detect?

A comprehensive vascular screening test is designed to catch four overlapping disease processes in symptomatic or at-risk patients:

• Peripheral arterial disease (PAD) — narrowing of lower-extremity arteries, identified by an ABI below 0.90 or, when arteries are calcified, by an abnormal TBI.
• Carotid artery stenosis — plaque buildup in the carotid arteries, a major stroke risk factor, identified by carotid duplex ultrasound.
• Abdominal aortic aneurysm (AAA) — focal dilation of the abdominal aorta, identified by abdominal ultrasound and graded by maximum diameter.
• Autonomic and sudomotor dysfunction — early signs of small-fiber neuropathy and dysautonomia, often present in diabetes, prediabetes, and cardiometabolic disease. These are picked up by HRV/Valsalva-based autonomic testing and quantitative sudomotor assessment, not by ABI or ultrasound alone. See our autonomic nervous system testing methods and sudomotor testing guide for the underlying physiology.

Bundling these components in one visit converts a vague “let’s keep an eye on it” plan into a documented, billable, and clinically meaningful workup. It also gives the physician an objective baseline to follow over time.

How Accurate Is the Ankle-Brachial Index Within a Vascular Screening Test?

The ABI is the backbone of any modern vascular screening test for PAD because it is fast, non-invasive, inexpensive, and well-validated against angiographic standards. A structured review reported that an ABI of 0.90 or lower achieves specificity in the range of 83% to 99% and accuracy of approximately 72% to 89% for detecting stenosis greater than 50%. Oscillometric ABI applied to femoropopliteal disease has shown sensitivity of approximately 97% and specificity of approximately 89%; doppler ABI in the same context shows sensitivity around 95% with specificity near 56%. Intraobserver variability in trained hands is low, around 7%.

The well-known limitation is that ABI sensitivity falls in patients with media calcification — most commonly long-standing diabetes and advanced chronic kidney disease — where the ankle arteries become non-compressible and ABI can be falsely normal or falsely elevated. That is why a complete vascular screening test pairs ABI with TBI (which uses the digital arteries, typically spared from calcification) and, ideally, pulse volume recording for waveform confirmation. The American Heart Association’s measurement and interpretation guidance for ABI supports this combined approach in higher-risk populations.

Who Should Receive a Vascular Screening Test?

Guideline-based screening for asymptomatic adults is nuanced. The US Preventive Services Task Force (USPSTF) currently gives a grade I (insufficient evidence) for ABI screening in asymptomatic adults without known PAD, CVD, or severe CKD. That grade does not mean ABI is unhelpful — it means the USPSTF has not found enough evidence to make a population-level for-or-against statement about routine screening in healthy asymptomatic adults.

For at-risk and symptomatic patients, the clinical picture is very different. Vascular societies and the AHA support objective ABI evaluation in patients with claudication symptoms, non-healing wounds, age over 65, diabetes with neuropathy, history of smoking, or other established cardiovascular disease. In practice, a vascular screening test is most useful for:

• Adults age 65+ with any cardiovascular risk factor
• Adults age 50+ with diabetes, hypertension, hyperlipidemia, or smoking history
• Patients reporting leg pain with walking that resolves with rest (classic claudication)
• Patients with non-healing foot wounds, ischemic rest pain, or known neuropathy
• Patients with established cardiovascular or cerebrovascular disease being evaluated for systemic atherosclerotic burden
• Medicare beneficiaries eligible for the SAAAVE Act AAA ultrasound — a one-time covered screening for men 65-75 who have smoked at least 100 cigarettes in their lifetime, and for individuals with a family history of AAA, when ordered during the Welcome to Medicare visit

For each of these groups, documenting risk factors and the clinical indication is the critical step that supports both medical decision-making and clean reimbursement.

How Do Independent Practices Add an In-Office Vascular Screening Test?

Most independent practices add vascular screening through one of three paths: refer to a vascular lab, partner with a mobile screening service, or perform the test in-house with a dedicated device. In-house has become substantially more practical with integrated platforms designed for primary care, cardiology, internal medicine, endocrinology, and pain management.

The TM-Flow System, distributed in the United States by HealthWright Technologies as part of the CMAT Advantage program, was built around exactly this use case. A single 7-10 minute test session delivers ABI/TBI and pulse volume recording (CPT 93922), cardiovagal autonomic testing (CPT 95921), and sudomotor function testing (CPT 95923). The device is FDA-cleared. Implementation typically includes device training, clinical protocols, payer credentialing support, and ongoing billing guidance — the elements that determine whether an in-house vascular screening test program actually generates the clinical and financial value it should. See our CMAT Advantage vs standard ABI testing comparison for a side-by-side view, and the PAD testing for independent practices article for the broader workflow.

Carotid duplex and AAA ultrasound remain separate modalities; many practices that perform in-house ABI/autonomic testing still refer carotid and AAA studies to a vascular lab. The combination of in-office ABI/autonomic/sudomotor testing plus referred carotid and AAA imaging gives a complete vascular screening test panel without requiring a full vascular ultrasound suite on site.

What Documentation Supports a Clean Vascular Screening Test Claim?

Reimbursement for a vascular screening test depends on documentation that ties the test to a clinical indication, not on the test itself. For each CPT code in the panel, the chart should include: documented risk factors or symptoms supporting medical necessity, the specific question the test was ordered to answer, the test performance details (date, equipment, protocol), a signed physician interpretation and report (not just the device printout), and ICD-10 codes consistent with the indication. Frequency limits typically range from one to two screening-indicated tests per year per patient under most payer policies; symptomatic or follow-up testing can be more frequent when the indication is documented.

Medicare reimbursement is set by the annual Physician Fee Schedule and varies by locality; verify current rates with the CMS PFS Look-up Tool. Rates for CPT 95921 and 95923 vary by Medicare locality; commercial payers commonly reimburse autonomic codes at 100% to 200% of the Medicare benchmark depending on contract. Practices should verify exact rates using the CMS PFS Look-up Tool and consult the AHA’s PAD patient resources for population context.

Frequently Asked Questions About Vascular Screening Tests

How long does a vascular screening test take?

A basic in-office vascular screening test using an integrated platform like TM-Flow takes 7 to 10 minutes for ABI, autonomic, and sudomotor measurements. A full panel that also includes carotid duplex and AAA ultrasound at a vascular lab typically takes under 30 minutes of patient time across the two studies. None of the components require contrast, radiation, or sedation.

Does Medicare cover a vascular screening test?

Medicare covers the diagnostic components of a vascular screening test when medical necessity is documented. ABI/TBI (CPT 93922) and autonomic and sudomotor testing (CPT 95921, 95923) are reimbursable under standard Medicare rules when the chart supports an appropriate indication. Medicare also covers a free one-time AAA ultrasound under the SAAAVE Act for at-risk beneficiaries during their Welcome to Medicare visit. Coverage of asymptomatic ABI screening varies — practices should verify medical necessity and indication-specific coverage with the relevant Medicare Administrative Contractor.

Is a vascular screening test the same as an EKG?

No. A vascular screening test evaluates the arteries — blood flow, vessel structure, and (in the case of autonomic add-ons) nerve control of cardiovascular function. An EKG records the electrical activity of the heart muscle. The two studies answer different clinical questions and are commonly ordered together when both cardiac and vascular workup is indicated. The TM-Flow System used in CMAT Advantage measures autonomic nervous system function, not EKG tracings.

How accurate is the ankle-brachial index in patients with diabetes?

ABI maintains high specificity in patients with diabetes but its sensitivity is limited in the presence of medial arterial calcification, which is more common in long-standing diabetes and advanced chronic kidney disease. In those patients, an ABI value can be falsely normal or falsely elevated. Pairing ABI with toe-brachial index (TBI) and pulse volume recording substantially improves diagnostic accuracy in this population because the digital arteries are typically spared from calcification.

Can a vascular screening test be performed when it is medically indicated for a symptomatic or at-risk patient?

Yes, when the medical indication is documented. Many practices integrate ABI/autonomic/sudomotor testing into the visit for at-risk or symptomatic patients with diabetes, hypertension, hyperlipidemia, or smoking history. Each CPT code in the vascular screening test panel is billed separately from the E/M code for the wellness visit, with appropriate modifiers when required by payer policy.

Ready to Add an In-Office Vascular Screening Test?

An in-office vascular screening test built around the CMAT Advantage program and the TM-Flow System gives independent practices a 7-10 minute, FDA-cleared, payer-recognized workflow for identifying PAD and small-fiber neuropathy risk earlier than symptoms alone allow. The clinical case is straightforward: 12 million Americans have PAD, most are undiagnosed, and earlier detection lets the physician change the cardiovascular risk trajectory.

To discuss the CMAT Advantage bundle, device pricing, training, payer credentialing, and implementation for your practice, contact HealthWright Technologies at contact@healthwrighttechnologies.com or call (678) 322-7146. Our office is at 60 Bear Creek Marina Road, Mansfield, GA 30055. Learn more on the products page, the partnership page, or the contact page.

Medical/billing disclaimer: This article is intended for licensed healthcare professionals and is for general informational purposes only. It does not constitute medical, billing, or legal advice. Clinical decisions about screening, diagnosis, and treatment should be based on individualized patient evaluation and current evidence. Reimbursement amounts and coverage vary by payer, region, and clinical indication; providers are responsible for verifying coverage and coding accuracy with each payer. CPT® is a registered trademark of the American Medical Association.